Mostrar el registro sencillo del ítem

dc.contributor.authorRetamozo, Soledad
dc.contributor.authorAkasbi, Miriam
dc.contributor.authorBrito Zeron, Pilar
dc.contributor.authorBoshc, Xavier
dc.contributor.authorBove, Albert
dc.contributor.authorPerez de Lis, Marta
dc.contributor.authorJimenez, Iratxe
dc.contributor.authorSoto Cardenas, Maria Jose
dc.contributor.authorRamos-Casals, Manel
dc.contributor.authorSoto Cardenas, María José 
dc.contributor.authorGandia, Miriam
dc.contributor.authorDiaz Lagares, Candido
dc.contributor.authorViñas, Odette
dc.contributor.authorSiso, Antoni
dc.contributor.authorPérez Alvarez, Roberto
dc.contributor.authorYagüe, Jordi
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.otherCirugíaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2026-04-08T11:24:05Z
dc.date.available2026-04-08T11:24:05Z
dc.date.issued2012
dc.identifier.issn1593-098X
dc.identifier.urihttp://hdl.handle.net/10498/39224
dc.description.abstractAbstract OBJECTIVES: To evaluate how determination of antibodies against the Ro52 antigen influences the classification and clinical characterisation of patients with suspected primary Sjögren`s syndrome (SS). METHODS: The cohort study included 187 patients who fulfilled at least four of the six 1993 SS classification criteria, including positive autoantibodies (antinuclear antibodies [ANA], rheumatoid factor [RF], anti-Ro/SSA and/or anti-La/SS-B antibodies) as mandatory criterium. Anti-Ro/SSA antibodies were tested by qualitative ELISA using a commercial assay. Anti-Ro52 antibodies were detected by a semiquantitative ELISA. RESULTS: Anti-Ro52 antibodies were found in 70/187 (37%) patients. A significant percentage of patients with anti-Ro/SSA antibodies were negative for anti-Ro52 antibodies (22%), while 13 patients (12%) were negative for anti-Ro/SSA antibodies but positive for anti-Ro52 antibodies, meaning that they fulfilled the 2002 SS criteria while avoiding the need for a salivary biopsy. Higher mean titers of anti-Ro52 antibodies were associated with severe scintigraphic involvement, positive salivary gland biopsy, parotid enlargement, anaemia, leukopenia and RF. A statistical correlation was found between anti-Ro52 titers and age, gammaglobulin levels, RF titers and serum IgA and IgG. Patients with positive anti-Ro/SSA and anti-Ro52 antibodies had a higher frequency of positive salivary gland biopsy, parotid enlargement and positive RF, and higher levels of serum IgG and IgA levels in comparison with patients with positive anti-Ro/SSA but negative anti-Ro52 antibodies. CONCLUSIONS: Anti-Ro52 antibodies were closely associated with the main clinical, histopathological and immunological features of primary SS. Anti-Ro52 autoantibody testing may help to identify a specific subset of SS patients with more aggressive disease, in whom a closer follow-up and earlier, more robust therapeutic management may be necessary.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherClinical and Experimental Rheumatology - 2012, vol. 30, nº 5, pp. 686-692es_ES
dc.sourceClinical and Experimental Rheumatologyes_ES
dc.subjectSjögren’s syndromees_ES
dc.subjectAnri-Ro/SSA antibodieses_ES
dc.subjectanti-Ro52 antibodieses_ES
dc.titleAnti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndromees_ES
dc.typejournal articlees_ES
dc.identifier.urlhttps://www.clinexprheumatol.org/abstract.asp?a=5286
dc.rights.accessRightsclosed accesses_ES
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem